1. Articles in category: Genetics

    1-24 of 246 1 2 3 4 ... 9 10 11 »
    1. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    2. A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

      A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

      Medicine (Baltimore). 2017 Dec;96(50):e8845

      Authors: Yuan LQ, Wang JH, Zhu K, Yang M, Gu WZ, Lai C, Li HM, Shu Q, Chen X

      Read Full Article
    3. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

      Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

      Curr Pediatr Rev. 2018 Jan 28;:

      Authors: Aygun N

      Abstract Neuroblastoma derived from primitive cells of the sympathetic nervous system typically develops in the adrenal medulla or paraspinal ganglia. Neuroblastoma usually occurs sporadically, but familial cases are also observed.

      Read Full Article
      Mentions: ALK MYCN PHOX2B
    4. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    5. Epigenetic regulation of neuroblastoma development.

      Epigenetic regulation of neuroblastoma development.

      Cell Tissue Res. 2018 Jan 19;:

      Authors: Kaat D, Frank S

      Abstract In recent years, technological advances have enabled a detailed landscaping of the epigenome and the mechanisms of epigenetic regulation that drive normal cell function, development and cancer.

      Read Full Article
    6. Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

      Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

      Oncotarget. 2017 Dec 08;8(64):107513-107529

      Authors: Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J

      Read Full Article
      Mentions: ALK MYCN
    7. Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.

      Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.

      Biochim Biophys Acta. 2017 Dec 13;:

      Authors: Yang L, Li Y, Wei Z, Chang X

      Abstract Neuroblastoma is a highly complex and heterogeneous cancer in children. Acquired genomic alterations including MYCN amplification, 1p deletion and 11q deletion are important risk factors and biomarkers in neuroblastoma.

      Read Full Article
      Mentions: MYCN Biomarkers
    8. Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

      Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

      Pediatric cancers tend to have relatively "quiet" genomes compared to tumors in adults. They harbor fewer discrete genetic mutations, especially in genes for readily "druggable" targets (such as protein kinases). Instead, these tumors tend to feature other kinds of genetic alterations, such as duplications or translocations.

      Read Full Article
      Mentions: MYCN
    9. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

      CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

      J Clin Invest. 2017 Dec 04;:

      Authors: Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K

      Read Full Article
      Mentions: MYCN
    10. MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.

      MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.

      Front Immunol. 2017;8:1473

      Authors: Zhang P, Wu X, Basu M, Dong C, Zheng P, Liu Y, Sandler AD

      Abstract Purpose: RNA and DNA sequencing data are traditionally used to discern intrinsic cellular pathways in cancer pathogenesis, their utility for investigating the tumor microenvironment (TME) has not been fully explored.

      Read Full Article
      Mentions: MYCN
    11. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

      Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

      J Natl Cancer Inst. 2017 Nov 01;109(11):

      Authors: Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J

      Read Full Article
    12. Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Transl Oncol. 2017 Oct 09;10(6):936-941

      Authors: He J, Zou Y, Wang T, Zhang R, Yang T, Zhu J, Wang F, Xia H

      Abstract Neuroblastoma is one of the most commonly diagnosed solid cancers for children, and genetic factors may play a critical role in neuroblastoma development.

      Read Full Article
    13. Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy

      Using data from a randomized phase III clinical trial of neuroblastoma patients (treated with or without immunotherapy) performed by the Children’s Oncology Group, researchers from the University of Wisconsin School of Medicine and Public Health found that a subset of patients, identified by the presence of a certain set of genes, were more likely to benefit from […]

      The post Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy appeared first on Healthcanal.com.

      Read Full Article
      Mentions: Immunotherapy
    14. Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Nat Commun. 2017 Sep 18;8(1):569

      Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H

      Read Full Article
      Mentions: MYCN
    15. Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Clin Cancer Res. 2017 Aug 22;:

      Authors: Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J

      Abstract PURPOSE: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20-30%) undergo consecutive recurrences with poor outcome.

      Read Full Article
    16. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2{alpha} to tumor suppression [Medical Sciences]

      Neuroblastoma is a pediatric cancer characterized by variable outcomes ranging from spontaneous regression to life-threatening progression. High-risk neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment. However, the overall survival remains low; hence, there is an urgent need for alternative therapeutic approaches. One feature...

      Read Full Article
    17. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Posted: July 24, 2017 240-760-6600 Credit: National Cancer Institute Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial.

      Read Full Article
      Mentions: Treatment COG
    18. NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

      Read Full Article
      Mentions: Treatment COG
    19. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.

      Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.

      Genes Chromosomes Cancer. 2017 Jan;56(1):28-41

      Authors: Marrano P, Irwin MS, Thorner PS

      Abstract Amplification of the MYCN gene in neuroblastoma is associated with a poor prognosis and is considered to remain unchanged in post-treatment specimens and metastases.

      Read Full Article
    1-24 of 246 1 2 3 4 ... 9 10 11 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) PHOX2B
    2. (1 articles) MYCN
    3. (1 articles) ALK
  4. General Informations in the News

    1. (1 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Relapse
    2. (1 articles) Refractory